Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794
Southwest Oncology Group (SWOG) trial 8794 demonstrated that adjuvant radiation reduces the risk of biochemical (prostate-specific antigen [PSA]) treatment failure by 50% over radical prostatectomy alone. In this analysis, we stratified patients as to their preradiation PSA levels and correlated it...
Saved in:
| Published in: | Journal of clinical oncology Vol. 25; no. 16; p. 2225 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.06.2007
|
| Subjects: | |
| ISSN: | 1527-7755, 1527-7755 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Southwest Oncology Group (SWOG) trial 8794 demonstrated that adjuvant radiation reduces the risk of biochemical (prostate-specific antigen [PSA]) treatment failure by 50% over radical prostatectomy alone. In this analysis, we stratified patients as to their preradiation PSA levels and correlated it with outcomes such as PSA treatment failure, local recurrence, and distant failure, to serve as guidelines for future research.
Four hundred thirty-one subjects with pathologically advanced prostate cancer (extraprostatic extension, positive surgical margins, or seminal vesicle invasion) were randomly assigned to adjuvant radiotherapy or observation.
Three hundred seventy-four eligible patients had immediate postprostatectomy and follow-up PSA data. Median follow-up was 10.2 years. For patients with a postsurgical PSA of 0.2 ng/mL, radiation was associated with reductions in the 10-year risk of biochemical treatment failure (72% to 42%), local failures (20% to 7%), and distant failures (12% to 4%). For patients with a postsurgical PSA between higher than 0.2 and <or = 1.0 ng/mL, reductions in the 10-year risk of biochemical failure (80% to 73%), local failures (25% to 9%), and distant failures (16% to 12%) were realized. In patients with postsurgical PSA higher than 1.0, the respective findings were 94% versus 100%, 28% versus 9%, and 44% versus 18%.
The pattern of treatment failure in high-risk patients is predominantly local with a surprisingly low incidence of metastatic failure. Adjuvant radiation to the prostate bed reduces the risk of metastatic disease and biochemical failure at all postsurgical PSA levels. Further improvement in reducing local treatment failure is likely to have the greatest impact on outcome in high-risk patients after prostatectomy. |
|---|---|
| AbstractList | Southwest Oncology Group (SWOG) trial 8794 demonstrated that adjuvant radiation reduces the risk of biochemical (prostate-specific antigen [PSA]) treatment failure by 50% over radical prostatectomy alone. In this analysis, we stratified patients as to their preradiation PSA levels and correlated it with outcomes such as PSA treatment failure, local recurrence, and distant failure, to serve as guidelines for future research.
Four hundred thirty-one subjects with pathologically advanced prostate cancer (extraprostatic extension, positive surgical margins, or seminal vesicle invasion) were randomly assigned to adjuvant radiotherapy or observation.
Three hundred seventy-four eligible patients had immediate postprostatectomy and follow-up PSA data. Median follow-up was 10.2 years. For patients with a postsurgical PSA of 0.2 ng/mL, radiation was associated with reductions in the 10-year risk of biochemical treatment failure (72% to 42%), local failures (20% to 7%), and distant failures (12% to 4%). For patients with a postsurgical PSA between higher than 0.2 and <or = 1.0 ng/mL, reductions in the 10-year risk of biochemical failure (80% to 73%), local failures (25% to 9%), and distant failures (16% to 12%) were realized. In patients with postsurgical PSA higher than 1.0, the respective findings were 94% versus 100%, 28% versus 9%, and 44% versus 18%.
The pattern of treatment failure in high-risk patients is predominantly local with a surprisingly low incidence of metastatic failure. Adjuvant radiation to the prostate bed reduces the risk of metastatic disease and biochemical failure at all postsurgical PSA levels. Further improvement in reducing local treatment failure is likely to have the greatest impact on outcome in high-risk patients after prostatectomy. Southwest Oncology Group (SWOG) trial 8794 demonstrated that adjuvant radiation reduces the risk of biochemical (prostate-specific antigen [PSA]) treatment failure by 50% over radical prostatectomy alone. In this analysis, we stratified patients as to their preradiation PSA levels and correlated it with outcomes such as PSA treatment failure, local recurrence, and distant failure, to serve as guidelines for future research.PURPOSESouthwest Oncology Group (SWOG) trial 8794 demonstrated that adjuvant radiation reduces the risk of biochemical (prostate-specific antigen [PSA]) treatment failure by 50% over radical prostatectomy alone. In this analysis, we stratified patients as to their preradiation PSA levels and correlated it with outcomes such as PSA treatment failure, local recurrence, and distant failure, to serve as guidelines for future research.Four hundred thirty-one subjects with pathologically advanced prostate cancer (extraprostatic extension, positive surgical margins, or seminal vesicle invasion) were randomly assigned to adjuvant radiotherapy or observation.PATIENTS AND METHODSFour hundred thirty-one subjects with pathologically advanced prostate cancer (extraprostatic extension, positive surgical margins, or seminal vesicle invasion) were randomly assigned to adjuvant radiotherapy or observation.Three hundred seventy-four eligible patients had immediate postprostatectomy and follow-up PSA data. Median follow-up was 10.2 years. For patients with a postsurgical PSA of 0.2 ng/mL, radiation was associated with reductions in the 10-year risk of biochemical treatment failure (72% to 42%), local failures (20% to 7%), and distant failures (12% to 4%). For patients with a postsurgical PSA between higher than 0.2 and <or = 1.0 ng/mL, reductions in the 10-year risk of biochemical failure (80% to 73%), local failures (25% to 9%), and distant failures (16% to 12%) were realized. In patients with postsurgical PSA higher than 1.0, the respective findings were 94% versus 100%, 28% versus 9%, and 44% versus 18%.RESULTSThree hundred seventy-four eligible patients had immediate postprostatectomy and follow-up PSA data. Median follow-up was 10.2 years. For patients with a postsurgical PSA of 0.2 ng/mL, radiation was associated with reductions in the 10-year risk of biochemical treatment failure (72% to 42%), local failures (20% to 7%), and distant failures (12% to 4%). For patients with a postsurgical PSA between higher than 0.2 and <or = 1.0 ng/mL, reductions in the 10-year risk of biochemical failure (80% to 73%), local failures (25% to 9%), and distant failures (16% to 12%) were realized. In patients with postsurgical PSA higher than 1.0, the respective findings were 94% versus 100%, 28% versus 9%, and 44% versus 18%.The pattern of treatment failure in high-risk patients is predominantly local with a surprisingly low incidence of metastatic failure. Adjuvant radiation to the prostate bed reduces the risk of metastatic disease and biochemical failure at all postsurgical PSA levels. Further improvement in reducing local treatment failure is likely to have the greatest impact on outcome in high-risk patients after prostatectomy.CONCLUSIONThe pattern of treatment failure in high-risk patients is predominantly local with a surprisingly low incidence of metastatic failure. Adjuvant radiation to the prostate bed reduces the risk of metastatic disease and biochemical failure at all postsurgical PSA levels. Further improvement in reducing local treatment failure is likely to have the greatest impact on outcome in high-risk patients after prostatectomy. |
| Author | Hussey, Michael A Crawford, E David Messing, Edward Forman, Jeffrey D Swanson, Gregory P Canby-Hagino, Edith Tangen, Catherine M Chin, Joseph Thompson, Ian M |
| Author_xml | – sequence: 1 givenname: Gregory P surname: Swanson fullname: Swanson, Gregory P email: gswanson@ctrc.net organization: Department of Radiation Oncology and Urology, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA. gswanson@ctrc.net – sequence: 2 givenname: Michael A surname: Hussey fullname: Hussey, Michael A – sequence: 3 givenname: Catherine M surname: Tangen fullname: Tangen, Catherine M – sequence: 4 givenname: Joseph surname: Chin fullname: Chin, Joseph – sequence: 5 givenname: Edward surname: Messing fullname: Messing, Edward – sequence: 6 givenname: Edith surname: Canby-Hagino fullname: Canby-Hagino, Edith – sequence: 7 givenname: Jeffrey D surname: Forman fullname: Forman, Jeffrey D – sequence: 8 givenname: Ian M surname: Thompson fullname: Thompson, Ian M – sequence: 9 givenname: E David surname: Crawford fullname: Crawford, E David |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17538167$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkM1LxDAQxYMo7ofePUlO3lqTNOm03mTRVVlYQcVjSdMJVNq0NulhwT_eqit48DLvDfPjwZsFOXSdQ0LOOIu5YOzyYbWNJ01jlsepzNUBmXMlIAJQ6vCPn5GF92-McZkl6pjMOKgk4ynMycfjgFXX1k67QMOAOrQ4OavrZhyQ1o72nQ_9MA0d0ISu3dFeh3qCPK09bTqjmyuqnW52fto7-3UOOLhv_2_i0-t2TTPI5Qk5srrxeLrXJXm5vXle3UWb7fp-db2JjEwhRMIqKXIGCWel1BwSCcxItEnODbMiLyGp0sowZkTFVMVLUJZleWYEgk0TFEty8ZM79Xgf0Yeirb3BptEOu9EXwBRw4NkEnu_BsWyxKvqhbvWwK37_JT4BgPhv-Q |
| CitedBy_id | crossref_primary_10_1038_s41391_018_0066_5 crossref_primary_10_1200_JCO_2007_14_2018 crossref_primary_10_3389_fonc_2016_00117 crossref_primary_10_1200_JCO_2014_59_0026 crossref_primary_10_1016_j_eururo_2013_11_002 crossref_primary_10_1016_j_ijrobp_2014_04_052 crossref_primary_10_1111_bju_13792 crossref_primary_10_1371_journal_pone_0103574 crossref_primary_10_1016_j_ctro_2021_07_003 crossref_primary_10_1111_iju_12049 crossref_primary_10_1080_14737140_2017_1378575 crossref_primary_10_1007_s00120_012_3030_3 crossref_primary_10_1007_s00345_015_1510_y crossref_primary_10_1016_j_urolonc_2009_07_019 crossref_primary_10_1111_bju_16819 crossref_primary_10_1001_jamaoncol_2025_0572 crossref_primary_10_1016_j_brachy_2013_09_008 crossref_primary_10_1016_j_ijrobp_2013_05_029 crossref_primary_10_1016_j_juro_2010_01_017 crossref_primary_10_1016_j_eursup_2010_02_012 crossref_primary_10_1016_j_suronc_2009_02_005 crossref_primary_10_1016_j_canlet_2011_12_006 crossref_primary_10_1177_030089161109700101 crossref_primary_10_1200_JCO_2016_67_9647 crossref_primary_10_1186_s12885_016_2572_y crossref_primary_10_1016_j_canrad_2021_08_017 crossref_primary_10_1016_j_urology_2011_01_061 crossref_primary_10_1016_j_brachy_2013_10_012 crossref_primary_10_1016_j_ijrobp_2009_01_078 crossref_primary_10_1016_j_brachy_2022_01_001 crossref_primary_10_1016_j_semradonc_2007_09_003 crossref_primary_10_1002_jmrs_240 crossref_primary_10_1007_s11912_015_0478_5 crossref_primary_10_1002_cam4_205 crossref_primary_10_1016_j_fpurol_2012_11_001 crossref_primary_10_1186_1748_717X_9_208 crossref_primary_10_14338_IJPT_20_00021_1 crossref_primary_10_1016_j_canrad_2007_10_003 crossref_primary_10_1111_bju_13229 crossref_primary_10_1016_j_ijrobp_2008_07_057 crossref_primary_10_1111_1754_9485_12431 crossref_primary_10_1016_j_meddos_2014_03_001 crossref_primary_10_3389_fonc_2021_780507 crossref_primary_10_1007_s00432_014_1673_8 crossref_primary_10_1097_MOU_0b013e3283449e06 crossref_primary_10_1007_s00345_021_03923_y crossref_primary_10_1007_s11547_012_0913_8 crossref_primary_10_1016_j_radonc_2008_03_019 crossref_primary_10_1016_S0140_6736_21_01790_6 crossref_primary_10_1016_j_ijrobp_2011_09_039 crossref_primary_10_1016_j_ejca_2015_07_019 crossref_primary_10_1016_j_ijrobp_2009_08_023 crossref_primary_10_1016_j_urolonc_2020_04_019 crossref_primary_10_1200_JCO_2008_18_9563 crossref_primary_10_1007_s00066_017_1172_3 crossref_primary_10_1016_j_canrad_2010_07_224 crossref_primary_10_1016_j_eururo_2008_09_051 crossref_primary_10_1016_j_urology_2015_03_012 crossref_primary_10_1016_j_euo_2018_04_014 crossref_primary_10_1016_j_eururo_2009_05_041 crossref_primary_10_1016_j_prro_2010_11_007 crossref_primary_10_1111_j_1464_410X_2009_09016_x crossref_primary_10_1016_j_ijrobp_2010_01_043 crossref_primary_10_1016_j_urology_2018_12_055 crossref_primary_10_1007_s00261_024_04408_3 crossref_primary_10_1155_2012_963417 crossref_primary_10_1007_s40258_014_0106_9 crossref_primary_10_1080_0284186X_2016_1223342 crossref_primary_10_1111_bju_16598 crossref_primary_10_1002_cncr_30665 crossref_primary_10_1016_j_ijrobp_2014_05_050 crossref_primary_10_1016_j_meddos_2017_05_003 crossref_primary_10_1016_j_ijrobp_2011_10_077 crossref_primary_10_1111_j_1464_410X_2007_07177_x crossref_primary_10_1186_s13550_016_0233_4 crossref_primary_10_1002_pros_22780 crossref_primary_10_1016_j_ijrobp_2008_07_026 crossref_primary_10_1016_j_ijrobp_2015_11_025 crossref_primary_10_1007_s13566_020_00413_3 crossref_primary_10_2217_fon_13_3 crossref_primary_10_1080_14737140_2017_1364994 crossref_primary_10_1038_nrclinonc_2010_207 crossref_primary_10_1016_j_urolonc_2007_05_022 crossref_primary_10_1007_s00345_023_04605_7 crossref_primary_10_1016_j_eursup_2008_01_017 crossref_primary_10_1016_j_radonc_2008_04_013 crossref_primary_10_1016_j_canlet_2022_215927 crossref_primary_10_1016_j_eururo_2014_10_036 crossref_primary_10_1016_j_euo_2023_02_013 crossref_primary_10_1016_j_juro_2013_05_032 crossref_primary_10_1016_j_urolonc_2011_06_007 crossref_primary_10_1016_S1470_2045_16_00111_X crossref_primary_10_1016_j_eururo_2009_05_039 crossref_primary_10_1016_j_acuroe_2012_01_001 crossref_primary_10_1007_s00120_008_1724_3 crossref_primary_10_1016_j_brachy_2010_10_002 crossref_primary_10_1080_14737140_2023_2181795 crossref_primary_10_1016_j_euf_2017_11_001 crossref_primary_10_1016_j_acuro_2011_03_011 crossref_primary_10_1016_j_ijrobp_2008_04_038 crossref_primary_10_1016_j_radonc_2008_05_009 crossref_primary_10_1038_pcan_2015_59 crossref_primary_10_1259_bjr_20150587 crossref_primary_10_1016_j_eururo_2007_12_035 crossref_primary_10_3389_fonc_2021_742093 crossref_primary_10_1016_S0959_8049_09_70027_9 crossref_primary_10_1200_JCO_2016_69_2509 crossref_primary_10_1016_j_ucl_2009_11_013 crossref_primary_10_1186_s12894_017_0262_y crossref_primary_10_1016_j_brachy_2008_08_007 crossref_primary_10_48095_cccu2012015 crossref_primary_10_1016_j_brachy_2008_08_005 crossref_primary_10_1007_s11934_010_0101_0 crossref_primary_10_1016_j_radonc_2009_12_031 crossref_primary_10_1016_j_urology_2013_03_043 crossref_primary_10_1007_s12149_012_0601_8 crossref_primary_10_1200_JCO_2008_16_1190 crossref_primary_10_1016_j_eururo_2013_09_016 crossref_primary_10_1016_j_ijrobp_2009_11_050 crossref_primary_10_1007_s00432_014_1738_8 crossref_primary_10_1016_j_brachy_2011_12_008 crossref_primary_10_1016_j_prro_2014_04_005 crossref_primary_10_1016_j_canrad_2014_07_149 crossref_primary_10_1016_j_ijrobp_2014_09_039 crossref_primary_10_1016_j_eururo_2007_07_005 crossref_primary_10_1093_annonc_mdr281 crossref_primary_10_1097_MOU_0b013e328338405d crossref_primary_10_1111_1754_9485_12043 crossref_primary_10_2217_fon_11_120 crossref_primary_10_1097_COC_0000000000000358 crossref_primary_10_1016_j_ijrobp_2009_02_049 crossref_primary_10_3389_fonc_2019_00012 crossref_primary_10_1016_j_ijrobp_2007_10_008 crossref_primary_10_1007_s13566_016_0248_5 crossref_primary_10_1016_j_euo_2018_09_005 crossref_primary_10_3389_fonc_2015_00204 crossref_primary_10_1007_s11095_010_0107_9 crossref_primary_10_1007_s00066_016_0990_z crossref_primary_10_1007_s11547_020_01149_3 crossref_primary_10_3389_fonc_2016_00048 crossref_primary_10_1016_j_ctro_2022_04_010 crossref_primary_10_1002_14651858_CD007234_pub2 crossref_primary_10_1016_j_eururo_2017_01_039 crossref_primary_10_1186_s13014_014_0303_6 crossref_primary_10_1002_cncr_27712 crossref_primary_10_1016_j_eururo_2011_10_010 crossref_primary_10_3892_mco_2019_1855 crossref_primary_10_1007_s00261_013_9998_3 crossref_primary_10_1016_j_ijrobp_2011_12_081 crossref_primary_10_1016_j_radonc_2012_11_014 crossref_primary_10_1016_j_radonc_2013_04_005 crossref_primary_10_1371_journal_pone_0079773 crossref_primary_10_1016_j_semradonc_2016_08_005 crossref_primary_10_1586_era_09_60 crossref_primary_10_3390_cancers13051133 crossref_primary_10_1016_j_ijrobp_2007_09_043 crossref_primary_10_1097_MOU_0b013e328361d3ed crossref_primary_10_1111_j_1464_410X_2012_11057_x crossref_primary_10_1007_s00120_010_2399_0 crossref_primary_10_1038_nrurol_2011_80 crossref_primary_10_1186_s12885_022_09493_5 crossref_primary_10_1016_j_juro_2008_08_037 crossref_primary_10_1186_1748_717X_6_44 crossref_primary_10_3760_cma_j_issn_0366_6999_20131549 crossref_primary_10_1016_j_prro_2019_09_016 crossref_primary_10_1016_j_eururo_2008_06_060 crossref_primary_10_1016_j_soc_2012_12_012 crossref_primary_10_1155_2012_259351 crossref_primary_10_1097_COC_0b013e31817e6ef9 crossref_primary_10_1016_j_clgc_2016_08_016 crossref_primary_10_1016_j_eururo_2014_01_020 crossref_primary_10_1097_CCO_0b013e3282f8b075 crossref_primary_10_1016_j_ijrobp_2008_12_059 crossref_primary_10_1007_s11934_017_0700_0 crossref_primary_10_1007_s13566_015_0199_2 crossref_primary_10_1016_j_ijrobp_2011_09_007 crossref_primary_10_1007_s11934_009_0033_8 crossref_primary_10_1016_j_prro_2016_10_010 crossref_primary_10_1038_s41598_023_50434_4 crossref_primary_10_1016_j_brachy_2012_08_002 crossref_primary_10_1016_j_eururo_2011_01_025 crossref_primary_10_1016_j_ijrobp_2008_06_1922 crossref_primary_10_1016_j_urology_2008_05_057 crossref_primary_10_1016_j_clgc_2014_09_002 crossref_primary_10_1016_j_eururo_2008_06_059 crossref_primary_10_1016_j_ijrobp_2010_04_039 crossref_primary_10_1016_j_ijrobp_2010_10_033 crossref_primary_10_1245_s10434_014_4183_7 crossref_primary_10_1016_j_clon_2009_10_015 crossref_primary_10_1016_j_eururo_2008_01_039 crossref_primary_10_12688_f1000research_7183_1 crossref_primary_10_1007_s11934_017_0698_3 crossref_primary_10_1016_j_juro_2013_04_078 |
| ContentType | Journal Article |
| CorporateAuthor | SWOG 8794 |
| CorporateAuthor_xml | – name: SWOG 8794 |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2006.09.6495 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| ExternalDocumentID | 17538167 |
| Genre | Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: CA38926 – fundername: NCI NIH HHS grantid: CA46441 – fundername: NCI NIH HHS grantid: CA32102 – fundername: NCI NIH HHS grantid: CA46113 – fundername: NCI NIH HHS grantid: CA45377 – fundername: NCI NIH HHS grantid: CA66636 – fundername: NCI NIH HHS grantid: CA35431 – fundername: NCI NIH HHS grantid: CA74647 – fundername: NCI NIH HHS grantid: CA14028 – fundername: NCI NIH HHS grantid: CA46136 |
| GroupedDBID | --- .55 .GJ 0R~ 18M 2WC 34G 39C 3O- 4.4 53G 5GY 5RE 8F7 8WZ A6W AARDX AAWTL AAYEP AAYOK ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AFFNX AI. AIAGR ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 KQ8 L7B LSO MJL N4W N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN SV3 TEORI TR2 TWZ UDS VH1 VVN WH7 X7M YCJ YFH YQY 7X8 ABBLC |
| ID | FETCH-LOGICAL-c467t-2f542907310b4a173470c4ef391c0f29b73d6dc00c2d05d1b75f0898c2e7f63e2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 239 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000247010400014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-7755 |
| IngestDate | Thu Sep 04 17:17:37 EDT 2025 Sat Sep 28 07:47:39 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 16 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c467t-2f542907310b4a173470c4ef391c0f29b73d6dc00c2d05d1b75f0898c2e7f63e2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2006.09.6495 |
| PMID | 17538167 |
| PQID | 70571718 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_70571718 pubmed_primary_17538167 |
| PublicationCentury | 2000 |
| PublicationDate | 2007-06-01 |
| PublicationDateYYYYMMDD | 2007-06-01 |
| PublicationDate_xml | – month: 06 year: 2007 text: 2007-06-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2007 |
| References | 18065746 - J Clin Oncol. 2007 Dec 10;25(35):5671-2 |
| References_xml | – reference: 18065746 - J Clin Oncol. 2007 Dec 10;25(35):5671-2 |
| SSID | ssj0014835 |
| Score | 2.3786864 |
| Snippet | Southwest Oncology Group (SWOG) trial 8794 demonstrated that adjuvant radiation reduces the risk of biochemical (prostate-specific antigen [PSA]) treatment... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2225 |
| SubjectTerms | Humans Male Neoplasm Metastasis Prospective Studies Prostate-Specific Antigen - blood Prostatectomy Prostatic Neoplasms - blood Prostatic Neoplasms - radiotherapy Prostatic Neoplasms - surgery Treatment Failure |
| Title | Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/17538167 https://www.proquest.com/docview/70571718 |
| Volume | 25 |
| WOSCitedRecordID | wos000247010400014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFH6oFfHiUre6zkE8GTuTbTIiiIhVhLYBFXsrk1mgB5NqqlDwxzuTxV4UD-YQAiEhZN68-Zjvve8DOGbSHAELndCzWzck4Q6TiXY08wIhE-pGmhdmE7TXiwYDFs_BRd0LY8sq65xYJGqZCbtH3qYGWBCTSC_Hr471jLLcamWgMQ8NzwAZG9N0MOMQ_Kiw17S-rQZDBkFFUpqwaN9f9ysegp2FPgt-h5fFMtNZ_d8HrsFKBS_RVRkP6zCn0iYsdSsCvQkncSlVPT1Fj7POq_wUnaB4JmI93YDP2CqJlnUy6LsaHWk-snXsaJSicZZPxrZnhFseInuZokqjNUejHBVr5DnileYJyrS9bXcfi-sf3_jw3L9FkZm6m_DUuXm8vnMqpwZHmEQ7cVxtba9MtiA48Tmhnk-x8JX2GBFYuyyhngylwFi4EgeSJDTQOGKRcBXVoafcLVhIs1TtACKKe9zgPkWp9JlwOeaCC0aV72OFGW_BUf37h2YmWHqDpyp7z4f1ALRguxzB4bgU7BhaNdKIhHT3z2f3YLkuCMRkHxra5AB1AIviYzLK3w6LADPnXtz9Agst3O4 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predominant+treatment+failure+in+postprostatectomy+patients+is+local%3A+analysis+of+patterns+of+treatment+failure+in+SWOG+8794&rft.jtitle=Journal+of+clinical+oncology&rft.au=Swanson%2C+Gregory+P&rft.au=Hussey%2C+Michael+A&rft.au=Tangen%2C+Catherine+M&rft.au=Chin%2C+Joseph&rft.date=2007-06-01&rft.issn=1527-7755&rft.eissn=1527-7755&rft.volume=25&rft.issue=16&rft.spage=2225&rft_id=info:doi/10.1200%2FJCO.2006.09.6495&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon |